Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,051 across all filing types
Latest filing 2019-07-11 Audit Report / Informat…
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Credit Rating
Audit Report / Information Classification · 95% confidence The document is a detailed credit rating report issued by Fitch Ratings for Glenmark Pharmaceuticals. It includes an in-depth analysis of the company's credit rating, financial leverage, business risks, product pipeline, market position, and liquidity. The report is dated July 11, 2019, and references fiscal years and financial metrics, indicating it is a substantive financial and credit assessment rather than a brief announcement or certification. The content is consistent with a standalone audit or credit rating report rather than an annual report, earnings release, or regulatory filing. It is not a simple announcement of a report publication but the full rating report itself. Therefore, the most appropriate classification is Audit Report / Information (AR). FY 2019
2019-07-11 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a licensing agreement between Glenmark Pharmaceuticals and Torrent Pharmaceuticals for co-marketing a drug in India. It contains no financial statements, regulatory filings, or detailed financial data. It is not an annual report, earnings release, or any form of financial report. It is a corporate announcement about a business collaboration and licensing agreement. Therefore, it fits best under the category of Capital/Financing Update (CAP), which includes updates on company fundraising, financing activities, or capital structure changes, and can also cover licensing agreements and partnerships related to business operations.
2019-07-11 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated July 9, 2019, announcing that Glenmark Pharmaceuticals has received ANDA approval from the U.S. FDA for Ranolazine Extended-Release Tablets. It is addressed to stock exchanges and includes a media release. The content is a corporate announcement about regulatory approval for a pharmaceutical product, not a financial report, earnings release, or management discussion. The document length is 3900 characters, which is relatively short and primarily serves as a notification rather than a detailed report. There is no financial data, no discussion of financial results, no meeting materials, or voting results. It is not a regulatory filing in the sense of compliance documents but rather a corporate announcement about product approval. This fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory or corporate announcements that do not fit other categories.
2019-07-09 English
Related Party Transactions
Remuneration Information Classification · 85% confidence The document contains a table of transactions related to CSR activities, remuneration of key management personnel, and sitting fees paid to non-executive directors. There is no indication of a full financial report, audit report, earnings release, or regulatory filing. The content focuses on remuneration and related party transactions, which aligns with disclosures typically found in Remuneration Information filings. The document length is short (1044 characters), and it does not appear to be an announcement or a report publication notice. Therefore, the best fit is Remuneration Information (DEF 14A).
2019-07-01 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received ANDA approval from the U.S. FDA for certain generic tablets. It is addressed to stock exchanges and includes a media release for immediate release. The content is an announcement of a regulatory approval event, not a financial report, earnings release, or management discussion. The document length is under 5,000 characters and it is primarily an announcement rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about product approval.
2019-06-28 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing a partnership agreement between Glenmark Pharmaceuticals and Novartis to promote, commercialize, and distribute respiratory products in Brazil. It is addressed to stock exchanges and includes a media release. There are no financial statements, regulatory filings, or detailed financial data. The content is a corporate announcement about a business partnership and commercial arrangement, not a financial report, earnings release, or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Capital/Financing Update. It is a general corporate announcement about a partnership, which is best classified under Regulatory Filings (RNS) as a miscellaneous regulatory announcement that does not fit other specific categories.
2019-06-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.